Osteoporosis pathophysiology: Difference between revisions

Jump to navigation Jump to search
Haleigh Williams (talk | contribs)
Haleigh Williams (talk | contribs)
Line 22: Line 22:


* The role of [[calcitonin]], a hormone generated by the [[thyroid]] that increases bone deposition, is less clear and probably less significant.<ref name=Raisz/>
* The role of [[calcitonin]], a hormone generated by the [[thyroid]] that increases bone deposition, is less clear and probably less significant.<ref name=Raisz/>
* The activation of osteoclasts is regulated by various molecular signals, of which the [[RANKL]] (receptor activator for[[NF-kB|nuclear factor κB]] ligand) is one of best studied. This molecule is produced by osteoblasts and other cells such as[[lymphocyte]]s, and stimulates [[RANK]] (receptor activator of nuclear factor κB). [[Osteoprotegerin]] (OPG) binds RANKL before it has an opportunity to bind to RANK, and hence suppresses its ability to increase bone resorption. RANKL, RANK and OPG are closely related to [[tumor necrosis factor]] and its receptors. The role of the [[Wnt signaling pathway|''wnt'' signalling pathway]] is recognized but less well understood.  
* The activation of osteoclasts is regulated by various molecular signals, of which the [[RANKL]] (receptor activator for [[NF-kB|nuclear factor κB]] ligand) is one of best studied. This molecule is produced by osteoblasts and other cells such as [[lymphocyte]]s, and stimulates [[RANK]] (receptor activator of nuclear factor κB). [[Osteoprotegerin]] (OPG) binds RANKL before it has an opportunity to bind to RANK, and hence suppresses its ability to increase bone resorption. RANKL, RANK and OPG are closely related to [[tumor necrosis factor]] and its receptors. The role of the [[Wnt signaling pathway|''wnt'' signalling pathway]] is recognized but less well understood.  


* Local production of [[eicosanoid]]s and [[interleukin]]s is thought to participate in the regulation of bone turnover, and excess or reduced production of these mediators may underlie the development of osteoporosis.<ref name=Raisz/>
* Local production of [[eicosanoid]]s and [[interleukin]]s is thought to participate in the regulation of bone turnover, and excess or reduced production of these mediators may underlie the development of osteoporosis.<ref name=Raisz/>

Revision as of 15:39, 9 December 2016

Osteoporosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Osteoporosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Life Style Modification
Pharmacotherapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Osteoporosis pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Osteoporosis pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Osteoporosis pathophysiology

CDC on Osteoporosis pathophysiology

Osteoporosis pathophysiology in the news

Blogs on Osteoporosis pathophysiology

Directions to Hospitals Treating Osteoporosis

Risk calculators and risk factors for Osteoporosis pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Cafer Zorkun, M.D., Ph.D. [2], Raviteja Guddeti, M.B.B.S.[3]

Overview

The pathophysiology of osteoporosis involves an imbalance between bone resorption and bone formation. Factors that contribute to the development of osteoporosis include advanced age, female sex and hypogonadism.

Pathophysiology

In normal bone, there is constant remodeling of bone matrix; up to 10% of all bone mass may be undergoing remodeling at any point in time. The process takes place in bone multicellular units (BMUs) as first described by Frost in 1963.[1] Bone is resorbed by osteoclast cells (which derive from the bone marrow), after which new bone is deposited by osteoblast cells. [2]

Gross Pathology

  • The three main mechanisms by which osteoporosis develops are:
    • An inadequate peak bone mass in which the skeleton does not develop sufficient levels of bone mass and strength during growth
    • Excessive bone resorption and breakdown by osteoclasts
    • Inadequate formation of new bone by osteoblasts

An interplay of these three mechanisms underlie the development of fragile bone tissue.[2]

  • Hormonal factors strongly determine the rate of bone resorption. Lack of estrogen, such as during menopause, increases bone resorption, while also decreasing the deposition of new bone that normally occurs in weight bearing bones. The amount of estrogen needed to suppress this process is lower that than the amount normally needed to stimulate the uterus and breast gland. The α-form of theestrogen receptor appears to be the most important in regulating bone turnover.[2]
  • The role of calcitonin, a hormone generated by the thyroid that increases bone deposition, is less clear and probably less significant.[2]
  • The activation of osteoclasts is regulated by various molecular signals, of which the RANKL (receptor activator for nuclear factor κB ligand) is one of best studied. This molecule is produced by osteoblasts and other cells such as lymphocytes, and stimulates RANK (receptor activator of nuclear factor κB). Osteoprotegerin (OPG) binds RANKL before it has an opportunity to bind to RANK, and hence suppresses its ability to increase bone resorption. RANKL, RANK and OPG are closely related to tumor necrosis factor and its receptors. The role of the wnt signalling pathway is recognized but less well understood.
  • Local production of eicosanoids and interleukins is thought to participate in the regulation of bone turnover, and excess or reduced production of these mediators may underlie the development of osteoporosis.[2]

Microscopic pathology

  • Trabecular bone is the sponge-like bone in the center of long bones and vertebrae. Cortical bone is the hard outer shell of bones. Trabecular bone is more active and more subject to bone turnover and to remodeling than cortical bone.
  • In osteoporosis not only is the bone density decreased, but the microarchitecture of bone is disrupted.
  • In osteoporosis, the weaker spicules of trabecular bone break ("microcracks"), and are replaced by weak bone. Common osteoporotic fracture sites such as the wrist, the hip, and the spine, have a relatively high trabecular bone to cortical bone ratio. These areas rely on trabecular bone for strength, and therefore the intense remodeling causes these areas to degenerate most when the remodeling is imbalanced. This is why fractures most commonly occur at these sites.

References

  1. Frost HM, Thomas CC. Bone Remodeling Dynamics. Springfield, IL: 1963.
  2. 2.0 2.1 2.2 2.3 2.4 Raisz L (2005). "Pathogenesis of osteoporosis: concepts, conflicts, and prospects". J Clin Invest. 115 (12): 3318–25. doi:10.1172/JCI27071. PMID 16322775.

Template:WS Template:WH